Metoclopramide is Metabolized by CYP2D6 and is a Reversible Inhibitor, but Not Inactivator, of CYP2D6

Overview

Journal Xenobiotica

Publisher Informa Healthcare

Specialties Biochemistry
Toxicology

Date 2013 Sep 10

PMID 24010633

Citations 21

Authors

Mara R Livezey

Erran D Briggs

Amanda K Bolles

Leslie D Nagy

Rina Fujiwara

Laura Lowe Furge

Affiliations

Soon will be listed here.

Abstract

1. Metoclopramide is a widely used clinical drug in a variety of medical settings with rare acute dystonic events reported. The aim of this study was to assess a previous report of inactivation of CYP2D6 by metoclopramide, to determine the contribution of various CYPs to metoclopramide metabolism, and to identify the mono-oxygenated products of metoclopramide metabolism. 2. Metoclopramide interacted with CYP2D6 with Type I binding and a Ks value of 9.56 ± 1.09 µM. CYP2D6 was the major metabolizer of metoclopramide and the two major products were N-deethylation of the diethyl amine and N-hydroxylation on the phenyl ring amine. CYPs 1A2, 2C9, 2C19, and 3A4 also metabolized metoclopramide. 3. While reversible inhibition of CYP2D6 was noted, CYP2D6 inactivation by metoclopramide was not observed under conditions of varying concentration or varying time using Supersomes(TM) or pooled human liver microsomes. 4. The major metabolites of metoclopramide were N-hydroxylation and N-deethylation formed most efficiently by CYP2D6 but also formed by all CYPs examined. Also, while metoclopramide is metabolized primarily by CYP2D6, it is not a mechanism-based inactivator of CYP2D6 in vitro.

Citing Articles

Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia.

Sato T, Kawabata T, Kumondai M, Hayashi N, Komatsu H, Kikuchi Y Int J Mol Sci. 2024; 25(23).

PMID: 39684938 PMC: 11642635. DOI: 10.3390/ijms252313228.

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Knuijver T, Ter Heine R, Schellekens A, Heydari P, Lucas L, Westra S J Psychopharmacol. 2024; 38(5):481-488.

PMID: 38519421 PMC: 11102648. DOI: 10.1177/02698811241237873.

Performance and Sensitivity of [Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.

Hernandez-Lozano I, Leterrier S, Mairinger S, Stanek J, Zacher A, Breyer L Mol Pharm. 2024; 21(2):932-943.

PMID: 38225758 PMC: 10848257. DOI: 10.1021/acs.molpharmaceut.3c01036.

Implementation of pharmacogenetic testing in oncology: -guided dosing to prevent fluoropyrimidine toxicity in British Columbia.

Wu A, Anderson H, Hughesman C, Young S, Lohrisch C, Ross C Front Pharmacol. 2023; 14:1257745.

PMID: 37745065 PMC: 10515725. DOI: 10.3389/fphar.2023.1257745.

Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers.

Fink F, Bognar M, Hengl P, Paulmichl M, Nofziger C Front Pharmacol. 2023; 14:1201566.

PMID: 37497103 PMC: 10366597. DOI: 10.3389/fphar.2023.1201566.

References

Bateman D, Craft A, Nicholson E, Pearson A . Dystonic reactions and the pharmacokinetics of metoclopramide in children. Br J Clin Pharmacol. 1983; 15(5):557-9. PMC: 1427723. DOI: 10.1111/j.1365-2125.1983.tb02090.x. View

Obach R, Walsky R, Venkatakrishnan K . Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos. 2006; 35(2):246-55. DOI: 10.1124/dmd.106.012633. View

Heydari A, Yeo K, Lennard M, Ellis S, Tucker G, Rostami-Hodjegan A . Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos. 2004; 32(11):1213-7. DOI: 10.1124/dmd.104.001180. View

Hanna I, Kim M, Guengerich F . Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch Biochem Biophys. 2001; 393(2):255-61. DOI: 10.1006/abbi.2001.2510. View

DIPALMA J . Metoclopramide: a dopamine receptor antagonist. Am Fam Physician. 1990; 41(3):919-24. View

Rowland P, Blaney F, Smyth M, Jones J, Leydon V, Oxbrow A . Crystal structure of human cytochrome P450 2D6. J Biol Chem. 2005; 281(11):7614-22. DOI: 10.1074/jbc.M511232200. View

Rydberg P, Gloriam D, Olsen L . The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics. 2010; 26(23):2988-9. DOI: 10.1093/bioinformatics/btq584. View

Silfeler I, Arica V, Arica S, Dogan M . Development of acute dystonia in three brothers due to metoclopramide. J Res Med Sci. 2012; 17(3):308-9. PMC: 3527052. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

10.

Hollenberg P, Kent U, Bumpus N . Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol. 2007; 21(1):189-205. DOI: 10.1021/tx7002504. View

11.

Desta Z, Wu G, Morocho A, Flockhart D . The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002; 30(3):336-43. DOI: 10.1124/dmd.30.3.336. View

12.

Chauret N, Dobbs B, Lackman R, Bateman K, Stresser D, Ackermann J . The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos. 2001; 29(9):1196-200. View

13.

Bertelsen K, Venkatakrishnan K, von Moltke L, Obach R, Greenblatt D . Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003; 31(3):289-93. DOI: 10.1124/dmd.31.3.289. View

14.

Huey R, Morris G, Olson A, Goodsell D . A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 2007; 28(6):1145-52. DOI: 10.1002/jcc.20634. View

15.

Rydberg P, Olsen L . Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem. 2012; 7(7):1202-9. DOI: 10.1002/cmdc.201200160. View

16.

Yuan R, Madani S, Wei X, Reynolds K, Huang S . Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002; 30(12):1311-9. DOI: 10.1124/dmd.30.12.1311. View

17.

Kulanthaivel P, Barbuch R, Davidson R, Yi P, Rener G, Mattiuz E . Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos. 2004; 32(9):966-72. View

18.

Evans D, Watt A, Nicoll-Griffith D, Baillie T . Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol. 2004; 17(1):3-16. DOI: 10.1021/tx034170b. View

19.

Hutzler J, Steenwyk R, Smith E, Walker G, Wienkers L . Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol. 2004; 17(2):174-84. DOI: 10.1021/tx034199f. View

20.

Seto Y, Guengerich F . Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J Biol Chem. 1993; 268(14):9986-97. View